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MitochondriaIn this mini-review/opinion article we describe evidence that multiple cellular and molecular alterations in
Alzheimer's disease (AD) pathogenesis involve perturbed cellular calcium regulation, and that alterations in
synaptic calcium handlingmay be early and pivotal events in the disease process.With advancing age neurons
encounter increased oxidative stress and impaired energy metabolism, which compromise the function of
proteins that control membrane excitability and subcellular calcium dynamics. Altered proteolytic cleavage of
the β-amyloid precursor protein (APP) in response to the aging process in combination with genetic and
environmental factors results in the production and accumulation of neurotoxic forms of amyloid β-peptide
(Aβ). Aβ undergoes a self-aggregation process and concomitantly generates reactive oxygen species that can
trigger membrane-associated oxidative stress which, in turn, impairs the functions of ion-motive ATPases and
glutamate and glucose transporters thereby rendering neurons vulnerable to excitotoxicity and apoptosis.
Mutations in presenilin-1 that cause early-onset AD increase Aβ production, but also result in an abnormal
increase in the size of endoplasmic reticulum calcium stores. Some of the events in the neurodegenerative
cascade can be counteracted in animal models by manipulations that stabilize neuronal calcium homeostasis
including dietary energy restriction, agonists of glucagon-like peptide 1 receptors and drugs that activate
mitochondrial potassium channels. Emerging knowledge of the actions of calcium upstream and downstream
of Aβ provides opportunities to develop novel preventative and therapeutic interventions for AD. This article
is part of a Special Issue entitled: 11th European Symposium on Calcium.opean Symposium on Calcium.
+1 410 558 8465.
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B.V.Published by Elsevier B.V.1. Cellular and molecular landscape of the brain in Alzheimer's
disease (AD)
To understand if and how alterations in neuronal Ca2+ handling
contribute to the symptoms of AD (cognitive impairment and
emotional disturbances), it is important to peer inside the brains of
AD patients and age-matched neurologically normal control subjects
using a range of technologies including magnetic resonance imaging
(MRI) in living subjects, and microscopy- and molecular biology-
based analyses of postmortem brain samples. Several major abnor-
malities have been described that typify the brain in AD. MRI image-
based measurements of the sizes of different brain structures in
patients with mild cognitive impairment (MCI) who later develop AD
have revealed progressive and profound reductions in the size of the
hippocampus, a brain region critical for the acquisition of memories
[1]. Gyri in the frontal, parietal and temporal lobes are also reduced in
size as the disease advances [2]. The results of (indirect) measure-
ments of regional cellular energy metabolism using positron emission
tomography to image relative levels of radiolabeled 2-deoxyglucose
uptake, or functional MRI-based imaging of cerebral blood ﬂow, have
also proven informative. Reductions in energy utilization in thetemporal and frontal lobes occur early in AD patients, even before
evidence of cognitive impairment [3].
Examination of brain tissue sections from AD patients and age-
matched control subjects have revealed several abnormalities in AD,
most notably the presence of so-called neuroﬁbrillary tangles (NFT) in
neurons in the same brain regions that shrink as the disease
progresses. At the molecular level, NFT have been shown to be
comprised of ﬁlamentous accumulations of the microtubule-associ-
ated protein tau. In contrast to tau in healthy neurons, the tau in NFT is
hyperphosphorylated and hyperacetylated [4]. A second major
feature of AD is excessive extracellular accumulation, in the form of
diffuse and compact ‘plaques’ of amorphous and ﬁbrillar aggregates of
amyloid β-peptide (Aβ). Aβ is a 40–42 amino acidpeptide cleaved from
amuch larger integralmembrane precursor protein (APP); the enzymes
that liberate Aβ are called β-secretase and γ-secretase. Excessive
production of the longer 42 amino acid form of Aβ (Aβ42) is strongly
implicated as a key event in AD pathogenesis because most, if not all,
mutations in APP and presenilin-1 (the enzymatic component of the γ-
secretase protein complex) that cause early-onset dominantly inherited
familial AD (FAD) increase the production of Aβ42 [5]. Moreover, Aβ42
has been shown to be toxic to neurons, especially when it is in the form
of small peptide oligomers that are in an active state of self-aggregation
[6,7]. Unfortunately, treatment strategies for AD based on inhibiting γ-
secretase to reduce Aβ production or immunotherapy to stimulate
removal of Aβ [8] have failed in clinical trials.
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brain are a reduction in the number of synapses and the death of
neurons. There are several lines of evidence that point to synapses as
the sites where the neurodegenerative process begins in AD. APP is
axonally transported and accumulates in presynaptic terminals, and
data suggest that Aβ is produced in high amounts in synaptic
terminals [9,10]. Synapses are particularly vulnerable to dysfunction
and permanent damage caused by Aβ as demonstrated in electro-
physiological experiments in which exposure of brain slices to Aβ
impairs synaptic plasticity [11,12], and studies of cultured neurons
and isolated synaptic terminals which have shown that Aβ can impair
synaptic membrane ion and glucose transporters, and can perturb
mitochondrial bioenergetics [13,14]. Recent high resolution in vivo
two-photon microscopy imaging studies have clearly shown an
intimate physical association between Aβ aggregates and degenera-
tion of neurites and synapses [15]. In addition, Aβ impairs axonal
transport which may contribute to intraneuronal accumulation of Aβ,
neuronal network dysfunction, and transneuronal spread of the
neurodegenerative process in AD [16,17].
2. The aging brain I: Oxidative and metabolic stress compromise
neuronal Ca2+ handling
The evidence that damage to cellular components by free radicals
contributes to the aging process throughout the body including the
brain is substantial. Levels of oxidatively-modiﬁed proteins, DNA and
lipids are elevated with advancing age in multiple brain regions of
humans and rodents [18–20]. The same oxidative modiﬁcations are
even more profound in vulnerable brain regions of AD patients
compared to age-matched control subjects [21–24]. Interestingly,
several genes encoding proteins involved in the regulation of
neuronal excitability accumulate oxidative DNA lesions [25], which
may contribute to disruption of neuronal Ca2+ homeostasis and
neuronal network dysfunction in aging and AD [26]. Studies of animal
models of AD, principally transgenic mice that overexpress mutant
human APP (alone or in combination withmutant presenilin-1 and/or
tau) have provided evidence that increased oxidative stress occurs in
neurons in association with the earliest stages of development of
discernable Aβ and tau pathologies [27]. Oxidative stress may
promote Aβ production [28] by increasing APP cleavage by both β-
and γ-secretases [29]. Elevated intracellular Ca2+ levels resulting
from age-related increases in oxidative stress and Aβ toxicity (see [30]
and section on Aβ and Ca2+ homeostasis below) may contribute to
the increased amyloidogenic processing of APP in AD [31].
Accompanying oxidative damage to neurons during brain aging is
a progressive impairment of the function of mitochondria. Imaging
studies of regional brain energy metabolism in human subjects have
demonstrated hypometabolism in the hippocampus and frontal
cortex during aging, which is predictive of subsequent development
of cognitive impairment and AD [32,33]. Studies of mitochondria
isolated from the brains of rodents of different ages have provided
evidence that the ability of mitochondria to generate ATP is
compromised with advancing age and that mitochondria from old
brain cells exhibit increased free radical-mediated damage [34].
Impaired cellular energy metabolism may render neurons vulnerable
to excitotoxic damage [35], particularly when neurons are faced with
the additional stresses of Aβ and tau accumulations [36].
Neurons utilize many of the same mechanisms for Ca2+ signaling
and restoration of transmembrane Ca2+ gradients as do other cell types
including: voltage-gated Ca2+ channels and a Ca2+-ATPase in the
plasma membrane; receptors for various ligands that are coupled to
inositol phospholipid hydrolysis and Ca2+ release from IP3-sensitive
endoplasmic reticulum (ER) Ca2+ stores; ER ryanodine receptor
channels that mediate Ca2+-induced Ca2+ release; and mitochondrial
Ca2+ uptake and release systems (see [37] and [38] for review). In
addition, neurons alsopossess unique systems for local Ca2+ signaling atsynapses including; presynaptic voltage-gated Ca2+ channels coupled
to the synaptic vesicle membrane fusion machinery [39]; postsynaptic
excitatory glutamate receptor channels which ﬂux either Na+ (AMPA
receptors) or Ca2+ (NMDA receptors) [40,41]; and Ca2+-binding
proteins [42].
Studies of animal and cell culture models have clearly shown that
the ability of neurons to regulate cellular Ca2+ levels and dynamics
properly is compromised byboth oxidative stress and impaired cellular
energymetabolism [43]. Membrane lipid peroxidation has particularly
disruptive effects on neuronal Ca2+ homeostasis. Lipid peroxidation
typically occurs when levels of cellular superoxide anion radical and
hydrogenperoxide are increased in the presence of even trace amounts
of Fe2+ or Cu+, resulting in the production of hydroxyl radical [23].
Hydroxyl radical attacks double bonds in membrane lipids, thereby
producing a range of aldehydes. The aldehydic product of lipid
peroxidation 4-hydroxynonenal (HNE) may play a particularly
prominent role in the disruption of neuronal Ca2+ homeostasis in
aging and AD because of its ability to covalently modify proteins on
cysteine, lysine and histidine residues. It has been demonstrated in
experimental models that HNE impairs the function of at least 5
proteins that are known to playmajor roles in neuronal Ca2+ signaling:
the plasma membrane Na+/K+-ATPase; the plasma membrane Ca2+-
ATPase; the neuronal glucose transporter GLUT3; voltage-gated Ca2+
channels [44–46]; and the glutamate transporter in astrocytes [47].
Decrements in levels of ATP and NAD+, the primary energy
substrates in neurons, are implicated in age-related cognitive
dysfunction and AD. These energy substrates are particularly critical
for the function and survival of neurons because neurons must
consume large amounts of energy to rapidly restore ion gradients
after synaptic activation and action potential generation. When
cellular energy levels are reduced in neurons, as occurs dramatically
during an ischemic stroke and more insidiously during aging and in
AD, the intracellular Ca2+ levels remain elevated as the result of
sustained inﬂux through glutamate- and voltage-gated channels in
combination with impaired ion-motive ATPase activities [48–50].
Depletion of NAD+ can be prevented by administering nicotinamide,
thereby enabling neurons to maintain intracellular Ca2+ levels low
enough to prevent damage and death [51].
3. The aging brain II: Impaired abilities to prevent and repair
cellular damage
While the bulk of the research on brain aging and AD has focused
on factors that damage neurons (oxidative stress, energy impairment,
Aβ, etc.), less emphasis has been placed on the possible failure of
molecular and cellular mechanisms that may protect neurons against
dysfunction and degeneration. That such intrinsic protective mechan-
isms exist and can determine whether or not a given person develops
late-onset AD is suggested by epidemiological data demonstrating
associations between lifestyle factors and the risk of AD. Two
examples are regular exercise and moderation in dietary energy
intake, both of which may reduce the risk of AD. For example a
population-based study provided evidence that regular exercise in
mid- or late-life is associated with reduced risk of mild cognitive
impairment; this beneﬁcial effect of exercise was dose-dependent
[52]. Another study demonstrated that a 6-month exercise program
resulted in signiﬁcant improvement in cognitive function in elderly
women [53]. Accumulating evidence suggests that overeating/obesity
and diabetes increase the risk of cognitive impairment in AD. For
example, an epidemiological study found that individuals on the
lower end of the calorie intake spectrum are at reduced risk for AD
[54], caloric restriction improves cognitive performance in the elderly
[55] and more individuals with diabetes exhibit cognitive impairment
and develop AD compared to those without diabetes [56,57]. Studies
of animal models of AD support the notion that exercise and
moderation in energy intake can retard the molecular and cellular
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voluntary exercise decreases the accumulation of Aβ in the brains of
APP mutant mice [58], and short-term (3 weeks) voluntary wheel
running improves cognitive performance in aged APPmutant ADmice
[59]. When transgenic mice that express mutant human APP,
presenilin-1 and tau (3xTgAD mice) were maintained on either
alternate day fasting or limited daily feeding (40% caloric restriction)
for 1 year, their learning and memory performance was superior to
that of 3xTgAD mice maintained on the usual ad libitum diet [60].
Diabetic mice exhibit several abnormalities in their hippocampus that
are associated with impaired cognitive function including reduced
long-term potentiation of synaptic strength and a decrement in
neurogenesis [61]. Collectively, the evidence suggests that a chronic
positive energy balance and diabetes adversely affect neuroplasticity
and cognitive function during aging, whereas a negative energy
balance in overweight subjects or a neutral energy balance in low
weight subjects promotes successful brain aging.
What is the mechanism(s) by which exercise and dietary energy
restriction protect the brain against age-related cognitive impairment
and AD? Several studies have shown that exercise [62] and energy
restriction [63,64] increase the production of brain-derived neuro-
trophic factor (BDNF). This likely contributes to the beneﬁcial effects
of exercise and energy restriction on cognition because BDNF plays
important roles in synaptic plasticity and neurogenesis, and BDNF can
protect neurons against oxidative and metabolic insults (see [65,66]
for review). Dietary energy restriction, exercise and BDNF can protect
neurons against dysfunction and death in experimental models in
which the damage to neurons is Ca2+-mediated including excitotoxic
seizures, ischemic stroke and AD [60,67–69]. Evidence that BDNF
signaling is impaired in AD includes: reduced levels of BDNF mRNA
and protein in vulnerable brain regions of AD patients compared to
age-matched control subjects [70]; a negative association between
cerebrospinal ﬂuid BDNF concentration and cognitive function in
elderly subjects [71]; reduced BDNF levels associated with Aβ
aggregation state in the brain in transgenic mouse models of AD
[72]; and Aβ impairs retrograde BDNF trafﬁcking/signaling [73].
Several different neurotrophic factors have been shown to prevent
cellular Ca2+ overload in cultured neurons in experimental models of
excitotoxic andmetabolic stress. For example, ﬁbroblast growth factor
2 (FGF2) protected cultured hippocampal neurons against death
induced by exposure to glutamate [74] or glucose deprivation [75] by
a mechanism involving suppression of Ca2+ overload. FGF2 also
protected cultured hippocampal neurons against Aβ-induced death,
again by stabilizing intracellular Ca2+ levels [76]. Insulin-like growth
factor 1 (IGF1) is another example of a neurotrophic factor that
promotes neuronal plasticity and survival, at least in part, by
modifying cellular systems that regulate Ca2+ dynamics. For example,
IGF1 protected cultured rat hippocampal and septal neurons against
death induced by glucose deprivation, and this protection was
associated with prevention of excessive elevation of intracellular Ca2+
levels [77]. A decrement in IGF1 signaling may play a role in AD
pathogenesis because levels of IGF1 expression and signaling are
reduced in brain tissue samples from AD patients compared to age-
matched control subjects [78]. Because IGF1 can protect neurons against
Aβ toxicity [79], a deﬁcit in IGF1 would be expected to render neurons
more vulnerable to being damaged by Aβ in AD.
A particularly interesting recent series of ﬁndings provide evidence
for a novel endo-neurocrine system that simultaneously enhances
peripheral glucose metabolism and engages a signaling pathway in
neurons that promotes their survival and adaptive plasticity. Gluca-
gon-like peptide 1 (GLP1) is produced in enteroendocrine cells in the
gut, from which it is released in response to food (particularly
carbohydrate) ingestion. GLP1 increases insulin production and
release from pancreatic β-cells and increases insulin sensitivity of
muscle and liver cells. The latter actions of GLP1 led to the
development of a longer-lasting synthetic peptide analog of GLP1called Exendin-4,which is nowused to treatmany patientswith type 2
diabetes [80]. We found that Exendin-4 reduces neuronal damage and
improves functional outcome in animal models of stroke, Parkinson's
disease and Huntington's disease [81,82]. GLP1 receptors are coupled
to Gs and cyclic AMP production resulting in the activation of the
transcription factor CREB,which then induces the expressionof a range
of genes involved in neuronal plasticity and survival including BDNF
and certain DNA repair enzymes [83,84]. Cell culture studies and in
vivo studies have shown that GLP1 receptor activation can prevent
aberrant elevations of intracellular Ca2+ levels in models of excito-
toxicity and Aβ toxicity [85–87]. Finally, two recent studies have
demonstrated beneﬁcial effects of GLP1 receptor agonists on Aβ
pathology and synaptic plasticity in mouse models of AD [88,89].
AD and other major age-related neurodegenerative disorders
involve abnormal intracellular accumulations of proteins which differ
somewhat amongst the disorders: tau and Aβ in AD, α-synuclein in
Parkinson's disease, and huntingtin in Huntington's disease. Increas-
ing evidence suggests that impaired cellular “garbage disposal”
mechanisms contribute to the build-up of the abnormal proteins.
The two major garbage disposal systems, the proteasome and the
autophagy/lysosome apparatus, become dysfunctional in AD [90,91].
Excessive elevations of intracellular Ca2+ levels may impair protea-
some function and autophagy [92,93] on the one hand, while
impaired proteasome and autophagy activity can result in dysregula-
tion of cellular Ca2+ homeostasis [94,95] on the other hand.
A ﬁnal example of a cytoprotective regulatory systemwithin neurons
that recent ﬁndings suggest is compromised during aging and AD is the
plasma membrane (PM) redox system (PMRS). The PM contains redox
enzymes that provide electrons for energy metabolism and recycling of
antioxidants such as coenzyme Q and vitamin E. PMRS enzymes include
NADH-ascorbate free radical reductase, NADH-quinone oxidoreductase
1, NADH-ferrocyanide reductase, NADH-coenzyme Q10 reductase and
NADH-cytochrome c reductase. In addition, the antioxidants α-tocoph-
erol and coenzyme Q10 are important components of the PMRS. We
found that caloric restriction, a manipulation that protects the brain
against aging and disease, increases activities of PMRS enzymes and
antioxidant levels (α-tocopherol and coenzyme Q10) in brain PMs
during aging [96]. Age-related increases in PM lipid peroxidation, protein
carbonyls, and nitrotyrosine were attenuated by caloric restriction, and
levels of PMRS enzyme activities were higher and markers of oxidative
stress were lower in cultured neuronal cells treated with serum from
calorie-restricted animals comparedwith those treatedwith serum from
ad libitum-fed control animals. Theseﬁndings suggest important roles for
the PMRS in protecting brain cells against age-related increases in
oxidative andmetabolic stress. By renderingmitochondria dysfunctional,
we found that the PMRS can sustain cellular redox state and viability [97].
The activity levels ofmultiple PMRS enzymeswas found to be reduced in
brain tissue samples from AD patients and 3xTgAD mice, suggesting a
role for compromised PMRS function in AD pathogenesis [98].
4. Disruption of neuronal Ca2+ homeostasis by amyloid β-peptide
Exposure of cultured human or rodent neurons to Aβ(1–40 or 1–42)
can result in an elevation of the resting intracellular Ca2+ concentration
and can render the neurons vulnerable to excitotoxicity [99]. The
cytotoxic actions of Aβ appear to require that the peptide is in the
process of self-aggregation because small oligomeric forms of Aβ are
particularly damaging to neurons [12,36]. The plasma membrane
appears to be the major site at which neurons are damaged by Aβ.
Two major mechanisms for such damaging effects of Aβ have been
described and both involve Ca2+ as a central mediator of Aβ's
pathological actions. First, when aggregating at the cell surface Aβ
generates reactive oxygen species (hydrogen peroxide and hydroxyl
radical) resulting inmembrane lipid peroxidation [100,101].Membrane
lipid peroxidation results in the generation of the toxic aldehyde 4-
hydroxynonenal which impairs the function of membrane ion-motive
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membrane depolarization, Ca2+ inﬂux and cellular energy depletion
[13,44,45,47]. That lipid peroxidation and 4-hydroxynonenal are pivotal
events in the toxic actionofAβ is suggested by the ability of antioxidants
that inhibit membrane lipid peroxidation and molecules that scavenge
4-hydroxynonenal toprotectneurons frombeingdamagedandkilledby
Aβ [13,101–103]. A second mechanism by which neuronal Ca2+
homeostasis might be disrupted by Aβ is that Aβ oligomers may form
Ca2+-permeable pores in the plasma membrane [104].
Studies of postmortem brain tissue samples from AD patients, and
of animal models of AD, support a role for disruption of neuronal
(particularly synaptic) Ca2+ regulation in the neurotoxic action of Aβ.
Evidence for hyperactivation of calpains (Ca2+-dependent proteases)
in neurons undergoing neuroﬁbrillary degeneration in AD has been
reported [105,106]. Imaging of Aβ deposits and intracellular Ca2+
levels in neurons in the brains of APP mutant mice have provided
convincing evidence that Aβ causes an aberrant elevation of Ca2+
levels in neurites [107]. A subsequent study provided evidence that
activation of the Ca2+-dependent phosphatase calcineurin mediates
Aβ-induced spine loss and dendritic degeneration [108]. Glutamate
receptor-mediated Ca2+ elevations have been reported to cause
changes in tau similar to those seen in neuroﬁbrillary tangles [109],
suggesting a pivotal role for aberrant neuronal Ca2+ regulation in the
neurodegenerative process in AD.
5. The α-secretase-derived secreted form of APP stabilizes neuronal
calcium homeostasis
While sequential cleavages of APP by β- and γ-secretases generate
Aβ, cleavage of APP in the middle of the Aβ sequence by α-secretase
generates a secreted form of APP called sAPPα [110]. sAPPα is believed
to be released from presynaptic terminals in response to electrical
activity and Ca2+ inﬂux [111]. However, hyper-excitation of neurons
can result in increased Aβ production [112], and presumably reduced
sAPPα production. When recombinant sAPPα is applied to cultured
hippocampal neurons, a rapid hyperpolarization of the membrane
occurs and Ca2+ responses to glutamate are dampened [113,114].
Whole cell patch clamp recordings demonstrated that sAPPα sup-
presses spontaneous action potential ﬁring, and that this results from
activation of high conductance charybdotoxin-sensitive K+ channels
[113]. The mechanism by which sAPPα prevents cellular Ca2+ overload
and protects neurons against excitotoxic and metabolic insults, and Aβ
toxicity, may involve activation of a membrane-associated guanylate
cyclase which generates cyclic GMP [115]. The latter signaling pathway
results in activation of cyclic GMP-dependent protein kinase which can
activate K+ channels, and may also enhance glucose and glutamate
transport in synaptic compartments [116]. Finally, sAPPα can protect
neurons against the cell death-promoting actions of presenilin-1
mutations (see Section 6 later) by stabilizing intracellular Ca2+ levels
[117]. A major impediment to further research on the biological
functions of sAPPα is that a receptor for sAPPα has not yet been
identiﬁed. The discovery of such a receptor would therefore be an
important advance in the ﬁeld.
6. Presenilin-1 mutations and perturbed endoplasmic reticulum
Ca2+ release in AD
Numerous families have been identiﬁed in which dominantly
inherited early-onset AD is caused by a missense mutation in the
presenilin-1 gene [118]. Affected individuals typically become
symptomatic when they are in their 40 s or 50 s. Presenilin-1 is the
enzymatic component of the γ-secretase enzyme complex that
cleaves APP to generate Aβ, and AD-causing mutations in preseni-
lin-1 increases the production of Aβ42 [119]. Presenilin-1 mutations
can adversely affect neurons by increasing the production of Aβ42
which then perturbs neuronal Ca2+ regulation as described inSection 4 previously. However, considerable evidence suggests that
AD-causingmutations in presenilin-1may disrupt a different function
of presenilin-1, a function in regulating endoplasmic reticulum (ER)
Ca2+ homeostasis.
In 1996 and 1997 we reported the results of experiments in which
we investigated different aspects of cellular Ca2+ homeostasis, and
cellular vulnerability to various insults, in cultured neural cells
expressing either mutant or wild-type presenilin-1 [120,121]. We
found that when challenged with agonists that release Ca2+ from IP3-
sensitive ER stores, cells expressing mutant presenilin-1 release much
more Ca2+ compared to cells expressing wild-type presenilin-1.
Further analysis indicated that, for an unknown reason, the
presenilin-1 mutations caused the ER to accumulate abnormally
large amounts of Ca2+ [120,121]. To better understand the con-
sequences of presenilin-1 mutations on neuronal Ca2+ regulation we
generated and characterized presenilin-1 mutant (M146V mutation)
knockin (PS1KI) mice. The mice exhibit no overt phenotypes and do
not exhibit learning and memory deﬁcits. However, neurons in the
hippocampus and cerebral cortex of the PS1KI mice exhibit increased
vulnerability to excitotoxic and ischemic injury [122,123]. Enhanced
Ca2+ release from the ER plays a pivotal role in the neuro-endangering
actions of mutant presenilin-1 because drugs that block Ca2+ release
through ryanodine receptors and overexpression of the Ca2+-binding
protein calbindin protect neurons against the adverse effects of the
presenilin-1 mutation [122,124,125]. Levels of ryanodine receptor are
increased in neurons expressing mutant presenilin-1 [126] and,
interestingly, though ER Ca2+ content is increased as the result of
presenilin-1 mutations, capacitative Ca2+ entry is impaired [127].
Synaptic Ca2+ dynamics are perturbed by presenilin-1 mutations.
For example, synapses of presenilin-1 mutant mice exhibit enhanced
elevations of cytoplasmic Ca2+ levels during exposure to depolarizing
agents, Aβ and a mitochondrial toxin compared with synaptosomes
from nontransgenic mice and mice overexpressing wild-type pre-
senilin-1 [128]. Treatments that buffer cytoplasmic Ca2+ or that
prevent Ca2+ release from the ER protected synapses against the
adverse effect of presenilin-1 mutations on mitochondrial function.
Interestingly, PS1KI mice exhibit enhanced long-term potentiation of
synaptic transmission at hippocampal CA1 synapses [129]. In a recent
study of 3xTgAD mice, it was found that young (presymptomatic)
mice exhibit exaggerated ryanodine receptor-mediated Ca2+ release
in synaptic areas in the CA1 region of the hippocampus which was
apparently due to increased expression of the ryanodine receptor 2
isoform [130]. Therefore, presenilin-1 mutations may actually
enhance synaptic Ca2+ responses early in the process of AD, while
at the same time rendering neurons vulnerable to excessive Aβ
production and excitotoxic damage. On the other hand, the perturbed
Ca2+ regulation caused by presenilin-1 mutations may impair
responses to neurotransmitters that normally employ Ca2+ as part
of their signaling mechanism. Thus, activation of muscarinic receptors
impairs LTP in hippocampal slices from PS1KI mice, whereas
acetylcholine enhances LTP in slices from wild-type mice [131]. The
latter study also provided evidence for a reduction in NMDA currents
in CA1 neurons of PS1KI mice, suggesting a potential mechanism
whereby presenilin-1 mutations may impair synaptic plasticity.
The molecular basis of the perturbed ER Ca2+ handling caused by
presenilin-1mutations is not yet established, but recent ﬁndings suggest
that at least somemutations result in the loss of a normal Ca2+ handling
function ofwild-type presenilin-1. Tu et al. [132] reported thatwild-type
presenilin-1 forms Ca2+ leak channels in the ER membrane, and that
presenilin-1 mutations disrupt this proposed function of presenilin-1.
The latter ﬁndingwould seem to provide an explanation for the previous
evidence that the ER Ca2+ pool is abnormally increased in neurons
expressing mutant presenilin-1. Other studies have provided evidence
that presenilin-1 interactswith IP3 receptor in the ER and that presenilin-
1 mutations alter the gating activity of the receptor so as to enhance its
opening and release of Ca2+ from the ER [133]. The results of
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derived from people with AD-causing presenilin-1 mutations or cortical
neurons from presenilin-1 mutant mice demonstrated that the pre-
senilin-1mutations increase the time that the IP3 receptor channelswere
in an open Ca2+ burst mode [134].
7. Involvement of mitochondrial disturbances in aberrant neuronal
Ca2+ handling in AD
As described in Section 2, there is considerable evidence that
neurons suffer from an energy deﬁcit for some time period before they
become dysfunctional and die in AD. Several alterations in mitochon-
dria have been documented in studies of: 1) postmortem brain tissue
samples from AD patients; 2) ‘cybrid’ cell lines derived by fusing
ﬁbroblasts from AD patients with tumor cells; and 3) experimental
cell culture and animal models of AD (see [135,136] for review).
Activity levels of several enzymes in the mitochondrial tricarboxylic
acid (TCA) cycle are reduced in brain tissue samples from AD patients
compared to samples from age-matched control subjects includingα-
ketoglutarate dehydrogenase complex, pyruvate dehydrogenase
complex, isocitrate dehydrogenase [137]. Interestingly, levels of two
other TCA cycle enzymes, malate dehydrogenase and succinate
dehydrogenase, were increased, perhaps as an attempt at an adaptive
response. Studies of cybrid cells provide evidence for multiple
structural and functional alterations inmitochondria fromAD patients
[138]. In another study, AD cybrids exhibited a major decrease in
mitochondrial complex IV activity and increased oxyradical produc-
tion, without a change in complex I activity [139]. Moreover, basal
cytosolic Ca2+ concentration was elevated in AD cybrid cells, and the
cells with AD mitochondria also restored Ca2+ levels more slowly
when challenged with carbachol, a muscarinic receptor agonist that
induces Ca2+ release from IP3-sensitive ER stores.
Alterations in mitochondria in ADmay occur, in part, as an indirect
result of the toxic actions of Aβ at the plasma membrane. Multiple
studies have documented alterations in the mitochondria of neurons
exposed to Aβ40 or Aβ42 including membrane depolarization,
accumulation of Ca2+, superoxide production, reduced ATP produc-
tion, increased ﬁssion, opening of membrane permeability transition
pores and triggering of apoptosis [140–142]. Mitochondrial superox-
ide production is believed to play an important role in the neurotoxic
actions of Aβ because exposure of neurons to Aβ results in increased
mitochondrial oxyradical production, and mitochondrial superoxide
dismutase (SOD2) protects neurons from being damaged and killed
by Aβ [143]. The cell death-promoting effects of presenilin-1
mutations also involve increased mitochondrial superoxide produc-
tion [144] and associated aberrant elevations of intracellular Ca2+
levels [128]. Direct actions of Aβ on mitochondria have also been
reported. In a recent study the authors found that mitochondria
lacking cyclophilin D, a key protein of the mitochondrial permeability
transition pore, are resistant to several adverse effects of Aβ including
mitochondrial swelling, calcium accumulation and oxyradical pro-
duction [145]. Cyclophilin D-deﬁcient cells are resistant to being killed
by Aβ. Interestingly, a recent study has linked transient openings of
permeability transition pores to bursts of superoxide production
[146]. Perhaps mitochondria in neurons subjected to the (oxidative,
metabolic and Ca2+-related) stresses of aging and Aβ accumulation
become unable to control permeability pore opening resulting in
uncontrolled superoxide production, further disruption of Ca2+
homeostasis and cell degeneration.
8. Conclusions and implications for novel approaches for the
prevention and treatment of AD
There aremultiple molecular and cellular changes that occur in the
brain during normal aging, and perhaps changes speciﬁc for AD as
well, that tend to destabilize Ca2+-handling systems in neurons.Increased oxyradical production and accumulation of oxidative
damage to proteins, lipids and DNA, and impaired mitochondrial
function, are among such major age-related alterations. Excessive
oxidative stress, particularly membrane lipid peroxidation, impairs
the function of synaptic ion-motive ATPases, glucose transporters and
glutamate transporters which may predispose neurons to Ca2+
overload, synaptic failure and degeneration of axons and dendrites
[23,36]. Similarly, compromised mitochondrial function may occur in
neurons during aging resulting in reduced levels of cellular ATP and
NAD+, both of which are critical for themaintenance of neuronal Ca2+
homeostasis [136]. Increased production and self-aggregation of
Aβ42, resulting from aging, genetic factors and/or environmental
factors can have particularly abrasive effects on Ca2+ handling
systems in neurons and in some individuals Aβ42 may be the pivotal
factor that accelerates synaptic dysfunction and neuronal death
(Fig. 1). Studies of presenilin-1 mutations that cause early-onset AD
have kindled an interest in ER Ca2+ regulation in AD pathogenesis,
implicating an aberrantly large accumulation of Ca2+ in the ER in the
disease process [147].
Cholinesterase inhibitors that can provide temporary improve-
ment in cognitive function are the most widely prescribed drug for AD
patients. Currently, the major focus of drug development programs
throughout the pharmaceutical industry and academia is on prevent-
ing Aβ production by targeting γ- and β-secretases, or enhancing Aβ
clearance using immunotherapy approaches [8,148]. Unfortunately,
however, a recent phase III clinical trial of a γ-secretase inhibitor not
only did not have a beneﬁcial effect, but instead accelerated the
cognitive decline in the AD patients [149]. Aβ immunotherapy trials
have also proven disappointing with severe side effects in many AD
patients undergoing active immunization [150], and in a recent
passive immunization trial in which a monoclonal Aβ antibody was
administered to AD patients there was no signiﬁcant effect of the Aβ
antibody in the primary efﬁcacy analysis [151].
The only drug that has been shown to slow the progression of AD
targets neuronal Ca2+ homeostasis. Memantine blocks Ca2+ inﬂux
through NMDA-responsive glutamate receptor channels, but only
when the membrane is depolarized and the channel is open [152]. A
controlled clinical trial of memantine in patients with moderate to
severe AD demonstrated its efﬁcacy in retarding disease progression
[153]. The results of preclinical studies suggest the potential beneﬁt of
drugs that target other Ca2+-regulating systems. For example, it was
recently reported that long-term treatment with diazoxide can
ameliorate learning and memory deﬁcits and Aβ and tau pathologies
in the 3xTgAD mouse model [154]. Diazoxide opens mitochondrial
ATP-sensitive K+ channels at low concentrations and plasma
membrane K+ channels at somewhat higher concentrations. Via
these two-site actions diazoxide reduces neuronal excitability,
decreases mitochondrial oxyradical production and protects neurons
against Ca2+ overload. Another approach is to stimulate the
production of endogenous neurotrophic factors (or administer
exogenous factors), such as BDNF, NGF and ﬁbroblast growth factor
which activate signaling pathways that modulate the expression of a
range of proteins involved in cellular Ca2+ regulation [155–158].
Finally, emerging evidence suggests that manipulations that
induce adaptive stress responses in brain cells may protect against
cognitive impairment in aging and AD. For example, exercise and
dietary energy restriction have been shown to stimulate the
production in brain cells of several proteins known to play important
roles in cellular responses to stress including BDNF, protein
chaperones, antioxidant enzymes and mitochondrial uncoupling
proteins [159–161]. Several transcription factors known to be
responsive to oxidative and metabolic stress are activated in brain
cells in response to exercise and/or dietary energy restriction
including CREB. It may be possible to mimic the effects of exercise
and dietary energy restriction on neuroplasticity and resistance to
disease using pharmacological agents [161]. Calcium likely plays roles
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Fig. 1. Factors and mechanisms that may preserve cognitive function during aging, or
that may promote the development of Alzheimer's disease. A. Increasing evidence
suggests that moderation in dietary energy intake, regular exercise and a cognitively
challenging lifestyle can promote maintenance of cognitive function during aging.
Pharmacological interventions that target one or more regulatory systems, such as
those listed, are being tested in translational research studies. These lifestyle and
pharmacological agents may act by inducing the expression of neurotrophic factors,
antioxidants, calcium-regulating proteins, and/or by modifying Aβ production and
clearance. In these ways, neuronal calcium regulation is maintained resulting in the
preservation of synaptic plasticity and cognitive function. B. Factors that may lead to
cognitive impairment and AD include excessive calorie intake, a sedentary and
cognitively impoverished lifestyle, diabetes and depression. Diets high in saturated fats
and cholesterol, and genetic factors (ApoE-e4 genotype), may increase the risk for late-
onset AD. Mutations in APP or presenilin-1 cause early-onset AD, and the disease
process in such individuals may be particularly difﬁcult to modify. AD develops when
levels of oxidative stress, cellular energy deﬁcits, dysregulation of calcium homeostasis
and Aβ accumulation become excessive. Evidence described in the text suggest that
perturbed neuronal (synaptic) calcium handling plays a pivotal role in the synaptic
dysfunction, neuronal degeneration and cell death that underlies cognitive impairment
in AD. Modiﬁed from reference [30].
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energy restriction on brain cells. We suggest that increased synaptic
activity is involved in the upregulation of BDNF that occurs in
response to exercise and dietary energy restriction. Some drugs that
have been shown to protect neurons against dysfunction and
degeneration in animal models of AD may also act by a hormesis
(adaptive stress response) mechanism. For example, the mitochon-
drial K+ channel opener diazoxide is known to cause energetic stress
[162], and an adaptive response to such stress may explain its
beneﬁcial effects in AD mice [154]. Targeting cellular Ca2+ handling
systems, either directly or indirectly through adaptive stress response
mechanisms, may prove effective in preventing neuronal degenera-
tion and sustaining neuronal function during aging and in AD.Acknowledgements
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